Investigational drug · Phase 3
DLBS1442
Also called: Dismeno
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Dysmenorrhea.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "DLBS1442"
First trial start
2026
Aug 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DLBS1442", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Dysmenorrhea
Largest trials
Live from ClinicalTrials.gov: studies naming "DLBS1442" as an intervention, largest first.
- The Efficacy and Safety of DLBS1442 in Patients With Primary DysmenorrheaPivotal-lookingRecruiting
Dexa Medica GroupIndustry
NCT07937462 · 210 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 2026
Drug: DLBS1442; Placebo · For: Primary Dysmenorrhea
Sites: Jakarta, Indonesia
- DLBS1442 for The Treatment of Pain in Patients Suspected EndometriosisPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT01942122 · 60 participants · Start Oct 2015 · Primary completion Feb 2021
Drug: DLBS1442 100; Mefenamic acid and 1 more · For: Endometrioma; Visual Analogue Pain Scale: Moderate or Severe Pain
Sites: Jakarta Pusat, Indonesia; Jakarta, Indonesia · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-inflammatory Effect of Predimenol, A Bioactive Extract from Phaleria macrocarpa, through the Suppression of NF-κB and COX-2.
Yuliana Y, Tandrasasmita OM, Tjandrawinata RR · Recent Adv Inflamm Allergy Drug Discov 2022
- Anti-inflammatory, antiangiogenic, and apoptosis-inducing activity of DLBS1442, a bioactive fraction of Phaleria macrocarpa, in a RL95-2 cell line as a molecular model of endometriosis.
Tandrasasmita OM, Sutanto AM, Arifin PF, et al. · Int J Womens Health 2015
- Symptomatic treatment of premenstrual syndrome and/or primary dysmenorrhea with DLBS1442, a bioactive extract of Phaleria macrocarpa.
Tjandrawinata RR, Nofiarny D, Susanto LW, et al. · Int J Gen Med 2011
Also in development for Primary Dysmenorrhea
- DEH113Phase 31 trial
EMS · Primary Dysmenorrhea
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.